Novo Nordisk has announced that two therapies will be listed on the Pharmaceutical Benefits Scheme on 1 July, expanding subsidised options for Australians with endocrine conditions.
Two new listings add treatment choices for growth hormone deficiency and people with type 1 diabetes
June 29, 2026 Latest NewsBioPharma
Latest Video
New Stories
-
Two new listings add treatment choices for growth hormone deficiency and people with type 1 diabetes
June 29, 2026 - - Latest News -
Officials highlight benefits but urge caution in rollout of AI-driven medical scribes
June 29, 2026 - - Latest News -
A comment that highlights how complexity is making the challenge more challenging
June 29, 2026 - - Latest News -
Surely this therapy is an example of our system at its absolute worst?
June 28, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 26 June
June 26, 2026 - - Podcast -
Arrotex and CStone partner to bring new anti PD-L1 therapy to Australia and New Zealand
June 26, 2026 - - Latest News -
Australia's next industry agreements might put more biologics squarely in the frame
June 26, 2026 - - Latest News


